Form 4: Theriva Biologics Director Acquires 75,000 Stock Options

John J. Monahan, a Director at Theriva Biologics, Inc. (TOVX), acquired 75,000 stock options with an exercise price of $0.241, granted on January 5, 2026.

Summary

• John J. Monahan, a Director of Theriva Biologics, Inc. (TOVX), acquired 75,000 stock options.
• The options have an exercise price of $0.241 per share.
• The transaction date for the acquisition was January 5, 2026.
• These stock options will vest pro rata on a monthly basis over 12 months, starting February 1, 2026.
• The expiration date for these options is January 4, 2033.
• Following this transaction, Mr. Monahan beneficially owns 75,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive, as a director acquiring stock options can indicate confidence in the company's future, aligning their interests with shareholders. However, it's a routine compensation event.

Positives

• A Director acquiring stock options can signal confidence in the company's future performance and aligns management's interests with shareholders.
• The options have a long expiration date (January 4, 2033), providing ample time for potential value realization.

Negatives

• No explicit negatives are typically reported in a Form 4 filing, which is purely transactional.

Risks

• The value of the stock options is dependent on the future stock price of Theriva Biologics, Inc. exceeding the exercise price of $0.241.
• If the company's stock price does not perform well, the options may expire worthless.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance, as it is solely a report of an insider transaction.

Industry Context

Insider transactions, such as the acquisition of stock options by a director, are closely watched by investors as they can provide insights into management's confidence in the company's prospects. Such grants are a common form of executive compensation designed to align the interests of directors and executives with those of shareholders.

Related Party Transactions

• John J. Monahan, a Director of Theriva Biologics, Inc., acquired 75,000 stock options, which constitutes a related party transaction as it involves an insider of the company.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can align their interests with shareholders, potentially motivating decisions that enhance long-term shareholder value.
• Employees: This transaction does not directly impact other employees, but it is part of the broader executive compensation structure.

Next Steps

• The acquired stock options will begin vesting on a pro rata monthly basis starting February 1, 2026, over a 12-month period.

Key Dates

Keywords

Theriva Biologics, TOVX, Stock Options, Insider Transaction, Form 4, Director, Equity Grant, Beneficial Ownership